MET and cancer: With regard to tumour grade there is no consensus, with some studies finding no association [6,36,48], other studies finding increased c-Met expression in high-grade tumours [46,49] and one study identifying more frequent immunoreactivity in grade 1 tumours compared with grade 3 cancers (75% versus 43.8%, respectively) [53].